• Something wrong with this record ?

Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder

E. Laukhtina, B. Pradere, U. Lemberger, PI. Karakiewicz, H. Fajkovic, SF. Shariat

. 2022 ; 32 (5) : 561-566. [pub] 20220715

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc22024541

PURPOSE OF REVIEW: In this review, we aimed to summarize the available evidence on pretreatment molecular biomarkers that may help to predict oncologic and pathologic outcomes in patients treated with neoadjuvant systemic therapy (NAST) for urothelial carcinoma of the bladder (UCB). RECENT FINDINGS: Several readily available and easily measurable blood-based biomarkers (e.g., neutrophil to lymphocyte or platelet-lymphocyte ratios) seems to help improve the selection of UCB patients who are most likely to benefit from NAST. Recent evidence suggests liquid biopsy including circulating tumor DNA (ctDNA) to be a promising tool to guide the administration of NAST in UCB patients. Pretreatment molecular and genetic characterization of transurethral resection of the bladder tumor samples may also help understand the tumor biology as luminal and basal tumor subtypes seems to be more responsive to NAST, while claudin-low and luminal-infiltrated tumor subtypes are less. In the context of neoadjuvant immunotherapy, programmed death-ligand 1 (PD-L1) status and ctDNA remain the only biomarker with possible value as the clinical utility of tumor mutational burden remains controversial/poor. SUMMARY: Biomarker approach is a necessary step to usher the age of precision/personalized medicine for muscle-invasive UCB with the overarching good to prevent both over- and under-therapy. The present review may offer a robust framework to compare and assess current and future molecular biomarkers for the selection of NAST in muscle-invasive UCB.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024541
003      
CZ-PrNML
005      
20221031100953.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001013 $2 doi
035    __
$a (PubMed)35849719
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
245    10
$a Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder / $c E. Laukhtina, B. Pradere, U. Lemberger, PI. Karakiewicz, H. Fajkovic, SF. Shariat
520    9_
$a PURPOSE OF REVIEW: In this review, we aimed to summarize the available evidence on pretreatment molecular biomarkers that may help to predict oncologic and pathologic outcomes in patients treated with neoadjuvant systemic therapy (NAST) for urothelial carcinoma of the bladder (UCB). RECENT FINDINGS: Several readily available and easily measurable blood-based biomarkers (e.g., neutrophil to lymphocyte or platelet-lymphocyte ratios) seems to help improve the selection of UCB patients who are most likely to benefit from NAST. Recent evidence suggests liquid biopsy including circulating tumor DNA (ctDNA) to be a promising tool to guide the administration of NAST in UCB patients. Pretreatment molecular and genetic characterization of transurethral resection of the bladder tumor samples may also help understand the tumor biology as luminal and basal tumor subtypes seems to be more responsive to NAST, while claudin-low and luminal-infiltrated tumor subtypes are less. In the context of neoadjuvant immunotherapy, programmed death-ligand 1 (PD-L1) status and ctDNA remain the only biomarker with possible value as the clinical utility of tumor mutational burden remains controversial/poor. SUMMARY: Biomarker approach is a necessary step to usher the age of precision/personalized medicine for muscle-invasive UCB with the overarching good to prevent both over- and under-therapy. The present review may offer a robust framework to compare and assess current and future molecular biomarkers for the selection of NAST in muscle-invasive UCB.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a karcinom z přechodných buněk $x farmakoterapie $x genetika $7 D002295
650    12
$a cirkulující nádorová DNA $x genetika $7 D000074141
650    _2
$a lidé $7 D006801
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a močový měchýř $x patologie $7 D001743
650    12
$a nádory močového měchýře $x farmakoterapie $x genetika $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France
700    1_
$a Lemberger, Ursula $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
700    1_
$a Fajkovic, Harun $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 32, č. 5 (2022), s. 561-566
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35849719 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100949 $b ABA008
999    __
$a ok $b bmc $g 1854328 $s 1175831
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 32 $c 5 $d 561-566 $e 20220715 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options